Welcome to our dedicated page for InMode Ltd. Ordinary Shares news (Ticker: INMD), a resource for investors and traders seeking the latest updates and insights on InMode Ltd. Ordinary Shares stock.
InMode Ltd. (NASDAQ: INMD) is a leading global provider of innovative medical technologies specializing in minimally and non-invasive surgical aesthetic and medical treatment solutions. The company's product portfolio spans three major energy-based treatment categories: face & body contouring, medical aesthetics, and women's health. Their products, such as BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, are widely utilized in plastic surgery, dermatology, gynecology, and ophthalmology.
InMode’s flagship products, including Fractora for skin texture improvement, Lumecca for photorejuvenation, Diolaze for hair removal, and BodyFX for body contouring, are designed to deliver effective and exciting aesthetic solutions.
InMode has consistently invested in research and development to expand its intellectual property portfolio, which is pivotal for maintaining its competitive edge. Recently, the company initiated legal action against BTL Industries for patent infringement regarding their radio-frequency based feminine rejuvenation products.
Despite market headwinds, including higher interest rates affecting equipment financing and slower purchase decisions, InMode has shown resilience with a 2% increase in Q3 2023 revenues, totaling $123.1 million. The company also saw a 13% rise in international sales during this period.
In Q1 2024, InMode announced pre-orders for two new platforms, IgniteRF and Optimus Max, which are anticipated to drive future growth. Additionally, a new share repurchase program and the appointment of Dr. Michael Anghel as Chairman of the Board underscore the company’s commitment to shareholder value.
InMode's innovative spirit is further highlighted by their recent partnership with P1 Offshore Racing, sponsoring the only female driver, Victoria Rand, signaling a strong commitment to empowering women.
For more detailed information and the latest updates, visit InMode's official website.
InMode Ltd. (NASDAQ: INMD), a global leader in innovative medical technologies, announced that its CFO Yair Malca and CMO Spero Theodorou will present at the Barclays Global Health Conference in Miami on March 15, 2023. The presentation is set for 9:30 am ET and will be moderated by equity research analyst Matt Miksic. Interested parties can access the webcast via InMode's Investor Relations website. InMode will also hold one-on-one investor meetings that day. For further details, visit the investor relations site.
InMode Ltd. (Nasdaq: INMD) reported record financial results for Q4 and FY 2022. Q4 revenue reached $133.6 million, a 21% increase from Q4 2021, with 83% from surgical technology platforms. GAAP net income for Q4 was $37.7 million, while non-GAAP net income hit $66.4 million. For the full year, revenues reached $454.3 million, a 27% increase, with GAAP net income of $161.5 million. Looking ahead, InMode forecasts revenue between $525 million and $530 million for 2023. Investors can expect a non-GAAP EPS of $2.58 to $2.60.
InMode Ltd. (Nasdaq: INMD) is set to announce its financial results for Q4 and the full year 2022 on February 14, 2023. Preliminary estimates indicate record revenues between $133.2 million and $133.4 million for Q4 2022, and $453.9 million to $454.1 million for the full year. Non-GAAP earnings per diluted share are expected to be $0.73 to $0.74 for Q4 and $2.38 to $2.39 for 2022. Additionally, the company projects 2023 revenues between $525 million and $530 million. InMode will hold a conference call on February 14 at 8:30 a.m. ET to discuss the results.
InMode Ltd. (Nasdaq: INMD) announced that its leadership team, including Moshe Mizrahy (CEO), Yair Malca (CFO), and Spero Theodorou (CMO), will present at the 25th Annual Needham Growth Conference on Jan. 12, 2023. The event, moderated by Mike Matson, starts at 10:15 am Eastern Time and will be accessible via webcast on InMode's Investor Relations website. Additionally, InMode will conduct in-person meetings on Jan. 11 and virtual meetings on Jan. 12.
InMode Ltd. (Nasdaq: INMD), a global leader in medical technologies, announced participation in three major investor conferences in November and December 2022. The events include:
- Jefferies London Healthcare Conference: Presentation on November 15 at 10:20 a.m. GMT
- Canaccord Genuity MTDF Conference: Presentation on November 17 at 1:00 p.m. ET
- Cantor Medical & Aesthetic Dermatology Conference: Panel on December 8 at 1:45 p.m. ET
Live webcasts will be available for each presentation. For more details, visit InMode's website.
InMode Ltd. (Nasdaq: INMD) reported a record-breaking revenue of $121.2 million for Q3 2022, marking a 29% increase compared to Q3 2021. The company achieved a GAAP net income of $48.8 million or $0.58 per diluted share, up from $44.7 million or $0.52 in the previous year. Non-GAAP net income reached $56.6 million with a non-GAAP EPS of $0.66. Significant growth was seen in consumables and services, increasing 53% year-over-year to $13.9 million. Management also increased revenue targets for the EmpowerRF platform and plans global expansion.
InMode Ltd. (Nasdaq: INMD) anticipates record third-quarter revenue between $120.5 million and $120.9 million, alongside a projected non-GAAP gross margin of 84% to 85% and earnings per diluted share ranging from $0.64 to $0.65. The company has also raised its full-year 2022 revenue guidance to between $445 million and $450 million. A conference call to discuss these results is scheduled for October 27, 2022, at 8:30 a.m. ET.
On September 29, 2022, InMode Ltd. (Nasdaq: INMD) announced actress Eva Longoria as its Global Brand Ambassador. Longoria, known for her work on Desperate Housewives and her philanthropic efforts, will promote InMode's innovative medical technologies. She has personally utilized InMode’s EvolveX Transform and Morpheus8 Body treatments to address post-pregnancy body changes, emphasizing their effectiveness. InMode develops and markets cutting-edge devices leveraging radiofrequency technology across multiple medical fields, striving to enhance surgical procedures and existing treatments.
InMode Ltd. (Nasdaq: INMD) announced that CFO Yair Malca will present at the Baird 2022 Global Healthcare Conference on Sept. 13, 2022, at 1:25 pm Eastern Time at the InterContinental New York Barclay hotel. The presentation will be webcast on InMode's Investor Relations website. Malca will also hold one-on-one investor meetings on Sept. 13 and Sept. 14. InMode specializes in innovative medical technologies, focusing on minimally invasive RF technologies applicable in various medical fields.
InMode Ltd. (NASDAQ: INMD), a leader in innovative medical technologies, announced participation in the 7th Annual Needham Virtual Med Tech & Diagnostics Conference on August 16, 2022. Senior management, including Chairman and CEO Moshe Mizrahy and CFO Yair Malca, will engage in one-on-one meetings with investors that day. Interested parties can schedule meetings via their Needham representatives. InMode develops cutting-edge devices using radiofrequency technology for various medical fields, emphasizing minimally invasive surgical solutions.
FAQ
What is the current stock price of InMode Ltd. Ordinary Shares (INMD)?
What is the market cap of InMode Ltd. Ordinary Shares (INMD)?
What products does InMode Ltd. offer?
What are InMode's core business categories?
Which markets does InMode serve?
How did InMode perform in Q3 2023?
What are some of InMode's flagship products?
What recent legal actions has InMode taken?
What new platforms has InMode recently announced?
Who is the new Chairman of InMode's Board?
What partnership has InMode recently entered into?
Where can I find more information about InMode?
